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Background: Diabetic cardiomyopathy is characterized by microvascular disease and interstitial ﬁbrosis, which
lead to progressive heart failure; however, its pathogenesis remains uncertain. Perfusion cardiac magnetic
resonance (CMR) has been proven efﬁcient to detect subclinical myocardial perfusion reserve abnormalities in
context of diabetes type 1 in the absence of epicardial coronary artery disease.
Objective: To evaluate myocardial perfusion reserve in patients with advanced cardiomyopathy and type 2
diabetes mellitus but without obstructive coronary artery disease (DM2). We hypothesized that impaired
myocardial perfusion reserve deteriorates as systolic dysfunction progresses.
Method and results:Meanmyocardial perfusion relative upslope at rest and during hyperaemia (adenosine 140 mg/
kg/min) andmean perfusion reserve index (MPRI), were examined in 11 clinically stable DM2 patients (mean (SD)
age 67 (8.4) years, range of 54–83 years; NYHA I–II; EF: 37.4 (11.3) %) using perfusion cardiac magnetic resonance
(CMR). Theywere compared against 16 patients with idiopathic cardiomyopathy (mean age: 62 (14.0) years, range
of 37–82 years; NYHA I–II; mean EF: 46 (12.3) %) and 10 healthy volunteers with normal ECG and no evidence of
cardiac disease (mean age 35 (11.2) years, range of 27–66 years; mean EF: 65 (5.1) %).
DM2patients had lower hyperemic perfusion relative upslope (0.2 (0.07) v. 0.31 (0.04) p= 0.001) andMPRI (0.736
(0.233) v. 2.35 (0.284), p = 0.001) compared to healthy subjects. Results of DM2 and DCM patients were similar.
MPRI in DM2 patents with moderate LV dysfunction was not different from patients with severe dysfunction.
Conclusion: In patients with DM2 myocardial perfusion reserve is markedly decreased, suggestive of microvascular
disease. In this small cohort MPRI impairment did not correlate to the LV EF deterioration.
© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
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Diabetic cardiomyopathy describes the presence of impaired
function in the absence of CAD or hypertension, in patients with a
background of diabetes. It represents a complex cardiac disorder with
involvement of myocardial, interstitial, coronary and neural alterations
[1]. Previous studies have shown that subclinical abnormalities of
functional indices of diastolic dysfunction and myocardial thickening
and more rarely of systolic dysfunction of both cardiac ventricles in
diabetes occur in the early stages of the disease [2,3].
Impaired myocardial perfusion reserve in diabetic heart disease,
suggestive ofmicrovascular dysfunction, has been previously described.
Microvascular dysfunction in diabetes is a multifactorial phenomenon,
related to anatomical but also functional properties alterations of the
myocardium. Animal and human experimental studies have identiﬁedder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Table 1
Clinical and CMR characteristics of patients and controls.
Parameters DM2 (n = 11) DCM (n = 16) Normal (n = 10)
Age, years (SD) 67 (8.4) 62 (14.0) 35 (11.2)
Gender, male (%) 7 (64) 11 (69) 5 (50)
NYHA (I/II/III/IV) 6/5/0/0 11/5/0/0 –
Angiography (any coronary lesion) 0 0 0
Hypertension 0 0 0
Type 2 diabetes mellitus 11/11 0 0
Microalbuminuria 6/11 5/16 0
Treatment
Beta-blocker
ACE/ARB
MR antagonist
Ivabradine
Oral hypoglycemic
Insulin
11/11
11/11
3/11
0
10/11
1/11
16/16
16/16
3/16
0
0
0
0
0
0
0
0
0
Function
LVEF (%)
LVEDV (ml)
LVESV (ml)
RVEF (%)
RVEDV (ml)
RVESV (ml)
LV mass
37.4 (11.3)
207.3 (56.5)
133 (51.2)
53.4 (14.0)
122.3 (45.1)
55.8 (22.1)
137.4 (35.7)
46 (12.3)
195 (47.7)
110 (44.1)
45.7 (14.8)
139.2 (40.1)
51.4 (23.8)
135 (44.0)
65 (5.1)⁎
135 (18.0)⁎
50 (10)⁎
64 (11.7)
169.4 (80.1)
93.0 (54.0)
93 (6)⁎
Myocardial perfusion
Inducible visual defect 0 0 0
Stress relative upslope 0.19 (0.03) 0.18 (0.07) 0.31 (0.04)⁎⁎
Rest relative upslope 0.27 (0.10) 0.26 (0.17) 0.14 (0.03)$
MPRI 0.736 (0.233) 0.844 (0.354) 2.35 (0.284)⁎⁎
LGE+ 0 0 0
Data are expressed as mean (SD) unless otherwise speciﬁed.
ACE: angiotensin-converting enzyme inhibitor, ARB: angiotensin receptor blocker, CMR: cardiac magnetic resonance, DM2: type 2 diabetic cardiomyopathy, DCM: idiopathic dilated
cardiomyopathy, LVEF: left ventricular ejection fraction, LVEDV: left ventricular end diastolic volume, LVESV: left ventricular end systolic function, LGE: late gadolinium enhancement,
MPRI: mean perfusion reserve index, MR:mineralocorticoid receptor, NYHA: New York Heart Association Classiﬁcation, RVEF: right ventricular ejection fraction, RVEDV: right ventricular
end diastolic function, RVESV: right ventricular end systolic function, and SD: standard deviation.
$ p b 0.1.
⁎ p b 0.05.
⁎⁎ p b 0.01.
20 K. Bratis et al. / IJC Metabolic & Endocrine 5 (2014) 19–23changes consistent with diabetic cardiomyopathy including peri-
vascular and interstitial ﬁbrosis [4], myocardial hypertrophy [5] and
endothelial proliferation with ﬁbrosis in small coronary arteries and
subsequent impaired perfusion reserve [6]. Impaired myocardial per-
fusion reserve in diabetes has been related to the level of autonomic
neuropathy [7,8] and diastolic dysfunction [9]. Current evidence on
the perfusion pattern of the diabetic myocardium in the advanced
stages of the disease, where overt global systolic function has been
established, is poor.
We aimed to evaluate myocardial perfusion patterns in a cohort of
type 2 diabetic cardiomyopathy patients with overt systolic dysfunction
with the use of adenosine perfusion CMR and compare them against
normal controls and patients with idiopathic dilated cardiomyopathy,
deﬁning a control group with known microvascular dysfunction and
absence of comorbidities. We hypothesized that impaired myocardial
perfusion reserve deteriorates as systolic dysfunction progresses. To
our knowledge, this is the ﬁrst study to examine myocardial perfusion
pattern in the advanced stages of the disease.2. Methods
2.1. Patients and controls
The study was conducted between September 2009 and December
2012 at Hippokration Hospital, Athens and St Thomas' Hospital,
London. Consecutive patientsmeeting theWHO criteria for type 2 diabe-
tes mellitus [10] and AHA echocardiographic criteria for LV systolic
dysfunction (left ventricle end diastolic diameter (LVEDV) N31 mm/m2
in men, N32 mm/m2 in women or LEFV b 45%) [11], without history of
hypertension, valvular disease or epicardial CAD (deﬁned by a normal
angiogram, less than 1 month prior to CMR exam) were invited toparticipate. Despite the rather stringent criteria for a population of se-
verely diseased diabetic patients, participants with microalbuminuria
(but normal renal function) were included in the study. Exclusion
criteriawere known contraindications for CMRor adenosine administra-
tion. The study protocol conformed to the ethical guidelines of the 1975
Declaration of Helsinki as reﬂected in a priori approval by the
institution's human research committee. Informed consentwas obtained
from each patient.
2.2. CMR protocol
All patients and controls underwent CMR at 1.5-T ﬁeld strength
using electrocardiographic gating and a 32-channel phased-array coil.
ECG-gated 2D steady-state free precession sequences were applied to
assess function in 2-chamber, 3-chamber, 4-chamber and short-axis
views. Turbo fast low-angle shot sequences (in-plane spatial resolution:
2.5 ∗ 2.5 ∗ 10mm)were used to evaluatemyocardialﬁrst-pass perfusion
in 3 short-axis slices during intravenous contrast medium infusion
(gadolinium at a dose of 0.1 mmol/kg body weight) with adenosine
(140 mg/kg/h), and at rest, after a 15-minute interval. After 10 min,
inversion recovery turbo fast low-angle shot was performed in 2-
chamber, 3-chamber, 4-chamber, and short-axis views to assessﬁbrosis.
Arterial blood pressurewas recorded by an automatic cuff sphygmoma-
nometer at one-minute intervals and the ECG was monitored continu-
ously throughout the adenosine infusion period. The mean duration of
the examination was 60 min.
2.3. CMR image analysis
CMR studies were analyzed by 2 cardiologists, who were blinded to
the patient details (KB, SM). The standard cine SSFP short axis was used
Fig. 1. Resting and hyperemic myocardial perfusion relative upslope (upper panel) and
perfusion reserve index (bottom panel) in patients with DM2, DCM and healthy controls.
DM2: type 2 diabetic cardiomyopathy, DCM: idiopathic dilated cardiomyopathy, and
MPRI: mean perfusion reserve index.
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volumes and calculate ejection fraction. A 16-segment model was
used for analysis of wall motion, visual perfusion and scar. Myocardial
wall motion was qualitatively analyzed and classiﬁed as normal or ab-
normal, which includes hypokinetic, dyskinetic, or akinetic wall seg-
ments. Mean myocardial perfusion was assessed both visually and
semi quantitatively. Intensity-over-time curves were generated for
rest and stress perfusion andwere used to calculate the relative upslope
deﬁned as the ratio between the maximum upslope of the selected
curve divided by the maximum upslope of the left ventricular cavity
curve (QMass MR 7.5, Medis medical imaging systems, Leiden,
Netherlands), according to the consensus recommendations of the
SCMR Task Force for post processing [12]. LV endocardial and epicardial
boundaries of the left ventricle were automatically outlined and manu-
ally edited for through-planemotion in time series of short-axis cineMR
images. The evaluation of myocardial scar tissue was performed from
the LGE images, based on a 5-standard deviation (SD) threshold above
the mean remote myocardial signal and was categorized as subendo-
cardial (b50% wall thickness) or transmural (N50% of wall thickness)
[13].
2.4. Statistical analysis
All data are reported as mean (SD). Statistical analysis was per-
formed using SPSS software (SPSS Inc., Chicago, IL, USA, version 21.0).
Stress/rest relative upslope and MPRI were compared between groupsusing 1-way analysis of variance (ANOVA) followed by Tukey's multiple
comparison test. The Student's unpaired t test was used to compare the
3 group demographic characteristics and correlation values were calcu-
lated using Pearson's correlation coefﬁcient. The coefﬁcient of variation
was calculated to study the variability of themeasurements. A p value of
b0.05 was considered statistically signiﬁcant. The intra and inter-
observer variability for MPRI wasmeasured using the intraclass correla-
tion coefﬁcient and was 0.88 and 0.85, respectively.
3. Results
3.1. Patients and controls
Eleven patients with type 2 diabetic mellitus and LV systolic dys-
function (7 males; mean age 67 (8.4) years, range of 54–83 years;
NYHA I–II, all euglycemic) were studied. CAD was excluded as per pro-
tocol. Duration of diabetes was N10 years in all. Two reference control
groups of 16 patients with DCM (11 males, 5 females; mean age 62
(14.0) years, range of 37–82 years; NYHA I–II) and 10 healthy volun-
teers with normal ECG and no evidence of cardiac disease (5 males, 5
females; mean age 35 (11.2) years, range of 27–66 years) were iden-
tiﬁed for comparison analysis.
Patients' clinical and CMR characteristics are presented in Table 1.
4. CMR results
All DM2 patients had impaired global systolic function (mean LVEF:
37.4 (11.3) %) (normal range: 67 (5) %),without any associated regional
wall motion abnormality and no late gadolinium enhancement sugges-
tive of the absence of anymyocardial scar. No inducible perfusion defect
was identiﬁed. All patients were in sinus rhythm.
4.1. Semi-quantitative analysis
4.1.1. MPRI in DM2 patients
Hyperemic relative upslope and MPRI were signiﬁcantly reduced in
DM2 patients compared to healthy controls (0.2 (0.07) v. 0.31 (0.04)
p = 0.001 and 0.736 (0.233) v. 2.35 (0.284), p = 0.001, respectively).
Resting relative upslope was signiﬁcantly lower in the control group v.
DM2 group (0.14 (0.03) v. 0.27 (0.10), p = 0.001) (Figs. 1 and 2). No
correlation was found in DM2 patients between MPRI and the severity
of LV dysfunction (LVEF: p = 0.8, r2 = 0.007; LVEDV: p = 0.274,
r2 = 0.099 and LVESV: p = 0.426, r2 = 0.072, respectively). Similarly,
there was no difference between those with severe (LVEF b 35%, n: 6)
and moderate systolic dysfunction (LVEF N 35%, n: 5) (0.73 (0.14)
v. 0.74 (0.34), p = 0.967). MPRI did not correlate with LV mass (p =
0.77, r2 = 0.1).
4.1.2. DM2 v. DCM patients
A group of 16 DCM patients (mean LVEF: 46 (12.3) %) (normal
range: 67 (5) %) was used as a comparison group. There was no sig-
niﬁcant difference in resting, hyperemic relative upslope and MPRI
between DM2 and DCM patients (0.27 (0.10) v. 0.27 (0.17), p = 1.0;
0.2 (0.07) v. 0.19 (0.07) p = 0.1 and 0.736 (0.233) v. 0.844 (0.354),
p = 0.791, respectively) (Figs. 1 and 2).
5. Discussion
Symptoms and signs suggestive of myocardial ischemia, as well as
reductions in myocardial perfusion reserve in the absence of coronary
disease are common in patientswith cardiomyopathies, although differ-
ent mechanisms are involved [14]. In DCM, structural abnormalities of
the vessels and reduced capillary density, in conjunctionwith abnormal
endothelial function can contribute to decreased perfusion reserve and
facilitate the occurrence of progressive worsening of LV dysfunction.
Impaired myocardial blood ﬂow has been documented in subclinical
Fig. 2. 16-segment bull's eyemap of relative upslope at stress (left) and at rest (right) in patients with DM2 (upper row), DCM (middle row) and normal controls (lower row). Hyperemic
myocardial perfusion relative upslope is signiﬁcantly impaired in DM2 and DCM. DM2: type 2 diabetic cardiomyopathy, DCM: idiopathic dilated cardiomyopathy.
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of poor prognosis for subsequent cardiac events, further progression of
heart failure and risk of death independently of the degree of LV func-
tion impairment and of the presence of overt heart failure [15].
The structure and function of the coronarymicrocirculationmay also
be abnormal inDM2. Vascular remodeling is the result of hyperglycemia
and impaired nitric oxide (NO) production,with a subsequent increased
production of glycated proteins and in particular an increase in endo-
thelial vascular growth factor (VEGF) [16,17]. Importantly, microvascu-
lar dysfunction secondary to metabolic alterations precedes clinically
signiﬁcant CAD. The increased incidence of HF and its poorer prognosis
in diabetic patients could suggest that the alterations in the underlying
myocardium, including microvascular dysfunction, render it more sus-
ceptible to ischemia, less able to recover after an ischemic insult and
to remodel appropriately.
Previous studies in patients with DM, no CAD and preserved LV sys-
tolic function show evidence of signiﬁcantly impaired myocardial per-
fusion reserve on non-invasive [18,19] and invasive [20] methods.
Recently, our group has demonstrated with the use of perfusion CMR
thatMPRI was severely impaired in young asymptomatic DM type 1 pa-
tients, representing the earliest abnormal ﬁnding of the disease, before
diastolic dysfunction, albuminuria and retinopathy occur [21]. However,
all the aforementioned studies have examined patients with subclinical
functional impairment andwere not able to show any relation between
subclinical changes in myocardial perfusion reserve and the degree of
disturbed function.This study shows that in diabetic type 2 patients with angiographic-
ally normal epicardial coronary arteries and heart failure, hyperemic
myocardial ﬂow and MPRI were markedly decreased, irrespective of
the functional impairment severity, demonstrating the substantial role
of coronary small-vessel disease in thediabetic heart. To our knowledge,
this is the ﬁrst study to examine perfusion reserve in patients with ad-
vanced LV systolic dysfunction and correlate it to the severity of the
disease.
The severity of MPRI impairment did not reach statistical signiﬁ-
cance when compared between DM2 patients with moderate and
severe LVEF. This ﬁnding is in agreement with previously published
evidence in other cardiomyopathies, in which no linear relation was
found between MBF and LVEF [22,23]. Microvascular dysfunction is
part of the underlying diabetic myocardial pathology, which also in-
cludes cellular, structural and metabolic disorders [24–27]. While the
prognostic value of impaired myocardial perfusion reserve in diabetes
has been previously examined [28], its relative causal role in the natural
evolution of diabetic heart failure remains to be determined.
Myocardial perfusion reserve impairment in DM2 patients was not
signiﬁcantly different when compared against DCM patients. Although
microvascular dysfunction is a substantial ﬁnding in the development
of different cardiomyopathies, the originating pathophysiological path-
way is different in each one of them. As thus, the detection, but not the
severity of microvascular disease should be considered as a potential
additive diagnostic parameter for the distinction between different
cardiomyopathies.
23K. Bratis et al. / IJC Metabolic & Endocrine 5 (2014) 19–23In the absence of relative regional differences in myocardial per-
fusion, abnormal perfusion reserve was demonstrated by quantitative
assessment analysis. Quantitative CMRperfusion inﬂuences substantial-
ly the appreciation of myocardial perfusion pattern in DM and provides
insight into its pathophysiological substrate [29].
Limitations of the study were: 1) the size of the cohort is small but
typical for an imaging study in this area. The presence of abnormal
perfusion pattern in all study subjects may indicate a high prevalence
of microvascular coronary dysfunction with potentially associated
myocardial ischemia in DM2. 2) To understand the impact of coronary
microvascular function in the natural evolution of the diabetic myocar-
dial disease a larger study conducted over a longer time is required. 3)
We used a convenient reference control sample that was not age
matched. 4) CMR was contradicted in patients with implanted devices.
6. Conclusion
In summary, in diabetic type 2 patients with angiographically
normal coronary arteries and heart failure a substantial reduction in
hyperemic myocardial reserve is observed irrespective of the functional
impairment severity. Microvascular dysfunction is part of the under-
lying diabetic myocardial pathology and its detection should be con-
sidered as a potential additive diagnostic parameter for the distinction
between speciﬁc types of cardiomyopathy.
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